Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (DE:XE7C)
FRANKFURT:XE7C
XE7C Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.30 - €5.59
Previous CloseN/A
Volume0.00
Average Volume (3M)439.00
Market Cap
$219.25M
Enterprise Value€69.15M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Feb 27, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding66,518,364
10 Day Avg. Volume110
30 Day Avg. Volume439
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)256.04
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit141.70
Enterprise Value/Ebitda-1.50
Forecast
1Y Price Target
€10.47Price Target Upside220.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Cardiff Oncology News
PremiumCompany Announcements
Cardiff Oncology Reports Promising Phase 2 Trial Results
PremiumCompany Announcements
Cardiff Oncology Reports Positive Q3 2024 Results and Clinical Progress---
Bulls Say, Bears Say
Bulls Say
Collaboration And Trial ActivationCardiff and its clinical operations partner Pfizer Ignite continue to activate trial sites (41 open vs. prior 33) and management reports enrollment demand is strong.
Drug Approval PotentialCRDF-005 trial may position onvansertib for accelerated approval based on an ORR interim analysis, with PFS and OS being the endpoints for full approval.
Financial StabilityCardiff's financial resources are sufficient to provide an operational runway through 3Q25, well beyond the data readout from the CRDF-004 trial.
Bears Say
Clinical TrialsNegative or poorer-than-anticipated clinical results for onvansertib in the ongoing CRDF-004 trial could pose significant risks.
Development TimelineDelays in advancing onvansertib into pivotal clinical studies could hinder progress and investor confidence.
Regulatory ApprovalFailure to obtain approval for onvansertib represents a considerable risk.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.57% Insiders
4.82% Mutual Funds
1.14% Other Institutional Investors
84.58% Public Companies and Individual Investors
XE7C FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was €1.30 and its highest was €5.59 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $219.25M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Feb 27, 2025 which is in 22 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Nov 07, 2024. The company reported -€0.24 earnings per share for the quarter, beating the consensus estimate of -€0.258 by €0.018.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 66,518,364 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -€0.24 in its last earnings report, beating expectations of -€0.258. Following the earnings report the stock price went down -22.302%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in DE:XE7C
---
Cardiff Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.47 (220.26% Upside)
€10.47 (220.26% Upside)
Blogger Sentiment
Bullish
DE:XE7C Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.69%
12-Months-Change
Fundamentals
Return on Equity
-67.57%
Trailing 12-Months
Asset Growth
-28.89%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
---
XE7C Stock 12 Month Forecast
Average Price Target
€10.47
▲(220.26% Upside)
Technical Analysis
Exelixis
―
Gilead Sciences
―
Karyopharm Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering XE7C
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+60.60%
reiterated a buy rating 3 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +60.60% per trade.
---